Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | FT576 |
| Trade Name | |
| Synonyms | FT-576|FT 576 |
| Drug Descriptions |
FT576 are iPSC-derived CAR-NK cells that have been engineered to express a recombinant IL-15/IL-15 receptor signaling complex, a high-affinity, non-cleavable CD16, and a chimeric antigen receptor targeted against BCMA, and to eliminate CD38 expression, which may lead to tumor regression and growth delay (Cancer Res 2021;81(13_Suppl):Abstract nr 1550). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C186430 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Daratumumab + FT576 | Daratumumab FT576 | 0 | 1 |
| FT576 | FT576 | 0 | 1 |